Gadolinium dose enhancement studies in microbeam radiation therapy.
Microbeam radiation therapy (MRT) is an innovative technique to treat brain tumors. The synchrotron generated x-ray beam, used for the treatment, is collimated and delivered in an array of narrow micrometer-sized planar rectangular fields. Several preclinical experiments performed at the Brookhaven National Laboratory (BNL) and at the European Synchrotron Radiation Facility (ESRF) have shown the sparing effect of the healthy tissue and the ablation of tumors in several animal models. It has also been determined that MRT yields a higher therapeutic index than nonsegmented beams of the same energy. This therapeutic index could be greatly improved by loading the tumor with high atomic number (Z) contrast agents. In this work, the dose enhancement factors and the peak to valley dose ratios (PVDRs) are assessed for different gadolinium (Z = 64) concentrations in the tumor and different microbeam energies by using Monte Carlo simulations (PENELOPE 2006 code). A significant decrease in the PVDR values in the tumor, and therefore a relevant increase in the dose deposition, is found in the presence of gadolinium. The optimum energy for the dose deposition in the tumor while keeping a high PVDR in the healthy tissues, which guaranties their sparing, has been investigated.
Prezado
Y
Y
ID17 Biomedical Beamline, European Synchrotron Radiation Facility, 6 Rue Jules Horowitz, Boîte Postale 220, 38043 Grenoble Cedex, France. prezado@esrf.fr
Fois
G
G
Le Duc
G
G
Bravin
A
A
D000818:Animals; D003287:Contrast Media; D005682:Gadolinium; D006257:Head / Q000528:radiation effects; D006801:Humans; D009010:Monte Carlo Method; D019047:Phantoms, Imaging; D011829:Radiation Dosage; D011878:Radiotherapy / Q000379:methods*; D011879:Radiotherapy Dosage; D051381:Rats
D003287:Contrast Media; D005682:Gadolinium